Lung Diseases Cies Search Engine [selected websites]

Oct 24, 2011

ChemDiv Research Institute at ChemRar Hi-Tech Centre : Collaboration and License Option agreement with Novartis Institute for Tropical Diseases to battle Tuberculosis

ChemDiv
October 6, 2011 - ChemDiv Research Institute (CDRI) at the ChemRar Hi-Tech Centre announced that it has signed collaboration and license option agreement with the Singapore based Novartis Institute for Tropical Diseases (NITD) to undertake discovery and development of patentable chemical compounds to find new, faster cures for Tuberculosis.

Chemical Diversity Research Institute CDRI

Tuberculosis (TB) is a major health problem in the world today, responsible for nearly 2 million deaths per year. One third of the world's population are infected with latent TB, and ~5-10% of infected individuals may develop active TB within their lifetime. Current treatment of TB takes more than half a year, much longer than treatment for other infectious diseases. Emergence of multi drug resistant tuberculosis and TB co-infection with HIV are escalating the need for finding new drugs for curing the TB.

novartis institutes for biomedical research

CDRI has prepared and delivered to NITD a focused library consisting of thousands of compounds that will be screened in a cell-based assay to identify lead molecules that are active against the mycobacterium... ChemDiv's Press Release -